phrykt

Puma Biotechnology, Inc. (PBYI): who owns it and who trades it

As of Nov 13, 2026, PBYI insiders reported 17 open-market sales worth $2.1M and no purchases in the last 12 months, with 94% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alan H Auerbach (CEO), with $569K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 13, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Puma Biotechnology

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PBYI

161 funds and institutions reported PBYI shares worth $315M at the end of Q2 2026, about 76% of the company. The largest holder is Acorn Capital Advisors, LLC with 8.1%.

Funds and institutions (13F) 76%Everyone else 24%

10 largest owners, by share of the company

Acorn Capital Advisors, LLC8.1%
BlackRock, Inc.7.5%
American Century Companies Inc4.6%
Acadian Asset Management LLC4.0%
Renaissance Technologies LLC3.6%
Vanguard Capital Management LLC3.6%
Vanguard Portfolio Management LLC3.6%
Lsv Asset Management3.2%
Dimensional Fund Advisors LP3.0%
Geode Capital Management, LLC2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Acorn Capital Advisors, LLC4.13M8.12%$33.5MNo change
BlackRock, Inc.3.80M7.48%$30.9M+6%
American Century Companies Inc2.32M4.56%$18.8M+21%
Acadian Asset Management LLC2.05M4.03%$16.6M+1%
Renaissance Technologies LLC1.84M3.61%$14.9M-5%
Vanguard Capital Management LLC1.84M3.61%$14.9M+1%
Vanguard Portfolio Management LLC1.83M3.59%$14.8M+5%
Lsv Asset Management1.62M3.18%$13.1M+37%
Dimensional Fund Advisors LP1.52M2.98%$12.3M+6%
Geode Capital Management, LLC1.34M2.63%$10.9M+32%
O'shaughnessy Asset Management, LLC1.12M2.21%$9.1M-1%
State Street Corp952,1651.87%$7.7M+4%
Kennedy Capital Management LLC873,2531.72%$7.1M-2%
Bridgeway Capital Management, LLC791,6161.56%$6.4M+2%
Ritholtz Wealth Management749,7981.47%$6.1M-3%
AQR Capital Management LLC725,1921.42%$5.9M-9%
Goldman Sachs Group Inc669,1561.31%$5.4M-0%
Northern Trust Corp652,3861.28%$5.3M+2%
Connor, Clark & Lunn Investment Management Ltd.642,9461.26%$5.2M-18%
UBS Group AG636,7611.25%$5.2M+19%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PBYI insiders reported $0 of open-market purchases and $2.1M of sales. 94% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.1M
17 trades, 10 people
Sales under a 10b5-1 plan
94%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$612K$612KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Michael Patrick MillerDirectorSale15,000$8.10$121KForm 4
Sep 14, 2026Troy Edward WilsonDirectorSale plan5,000$9.10$45.5KForm 4
Sep 14, 2026Alessandra CesanoDirectorSale plan62,150$9.12$567KForm 4
Jul 6, 2026Alan H AuerbachCEOSale plan44,058$8.26$364KForm 4
Jul 6, 2026Douglas M HuntSee RemarksSale plan8,460$8.26$69.9KForm 4
Jul 6, 2026Maximo F NouguesCFOSale plan9,386$8.26$77.5KForm 4
Jun 12, 2026Troy Edward WilsonDirectorSale plan10,800$7.20$77.8KForm 4
Jun 12, 2026Brian M StuglikDirectorSale plan8,100$7.20$58.3KForm 4
Jun 12, 2026Adrian SenderowiczDirectorSale plan27,000$7.20$194KForm 4
Jun 12, 2026Jay M MoyesDirectorSale plan22,000$7.22$159KForm 4
Jun 12, 2026Allison DorvalDirectorSale plan11,610$7.20$83.6KForm 4
Jan 7, 2026Alan H AuerbachCEOSale plan18,012$5.88$106KForm 4
Jan 7, 2026Douglas M HuntSee RemarksSale plan5,014$5.88$29.5KForm 4
Jan 7, 2026Maximo F NouguesCFOSale plan6,405$5.88$37.7KForm 4
Jan 6, 2026Alan H AuerbachCEOSale plan16,938$5.84$98.9KForm 4
Jan 6, 2026Douglas M HuntSee RemarksSale plan3,973$5.84$23.2KForm 4
Jan 6, 2026Maximo F NouguesCFOSale plan4,540$5.84$26.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Alan H AuerbachPresident and CEO, Director, 10% owner–$569KJul 6, 2026
Alessandra CesanoDirector–$567KSep 14, 2026
Adrian SenderowiczDirector–$194KJun 12, 2026
Jay M MoyesDirector–$159KJun 12, 2026
Maximo F NouguesChief Financial Officer–$142KJul 6, 2026
Troy Edward WilsonDirector–$123KSep 14, 2026
Douglas M HuntSee Remarks–$123KJul 6, 2026
Michael Patrick MillerDirector–$121KNov 11, 2026
Allison DorvalDirector–$83.6KJun 12, 2026
Brian M StuglikDirector–$58.3KJun 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PBYI short interest

Moderate short interest. 8.3% of PBYI shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went up 2%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.30M PBYI shares were sold short, 8.3% of the shares outstanding, down 5.3% from the report before. At the average daily volume of 373,513 shares, buying them all back would take about 11.5 trading days (days to cover).

Shares short, % of all shares

8.33%May 15Oct 309.05%

Days to cover

11.5May 15Oct 3021.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.30M8.33%-5%373,51311.5
Oct 15, 20264.54M8.80%+6%352,63912.9
Sep 30, 20264.26M8.26%-1%304,28914.0
Sep 15, 20264.32M8.37%+1%313,11913.8
Aug 31, 20264.27M8.28%+3%273,61015.6
Aug 14, 20264.17M8.07%+1%365,78111.4
Jul 31, 20264.13M8.11%+6%297,12713.9
Jul 15, 20263.91M7.68%+8%367,13210.7
Jun 30, 20263.63M7.13%-2%428,3678.5
Jun 15, 20263.70M7.27%-3%200,92818.4
May 29, 20263.80M7.47%-9%192,76819.7
May 15, 20264.19M8.24%+2%355,79011.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Puma Biotechnology company events

Puma Biotechnology filed 5 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jun 16, 2026VoteReported shareholder vote results. Filing
  4. May 7, 2026ResultsReleased financial results. Filing
  5. Feb 26, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Puma Biotechnology financials

Famous investors that hold PBYI

1 of the 50 well-known investors we track reported holding PBYI in their latest 13F filing. The largest position is Jim Simons's, worth $18.7M.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.88M$18.7M0.0%+3%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named PBYI in the last 120 days.

FiledHolderFormStake
Oct 6, 2026Alan H. Auerbach13D/A16.0%
Oct 6, 2026Alan H. Auerbach13D/A16.0%

Questions about Puma Biotechnology, Inc. (PBYI) stock

Who owns the most PBYI stock?

The largest reported owner of Puma Biotechnology, Inc. (PBYI) is Acorn Capital Advisors, LLC, with 8.1% of the company. In total, 161 funds and institutions reported holding PBYI at the end of Q2 2026, together about 76% of the shares. See the largest owners.

Are PBYI insiders buying or selling?

In the last 12 months, PBYI insiders reported no open-market purchases and 17 sales worth $2.1M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in PBYI?

As of Oct 30, 2026, 4.30M PBYI shares were sold short, 8.3% of the shares outstanding, down 5.3% from the report before. At the average daily volume of 373,513 shares, buying them all back would take about 11.5 trading days (days to cover). See the history.

Which famous investors hold PBYI?

1 of the 50 well-known investors we track reported PBYI in their latest 13F filing, including Jim Simons. The largest position is worth $18.7M. See all holders.

Executive pay

Puma Biotechnology's chief executive was paid a total of $3.1M for the year ended Dec 31, 2025, down 23% from $4M the year before. In the last 12 months, Puma Biotechnology's executives and directors bought no stock on the open market and sold $2.1M.

Chief executive, total pay$3.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$4.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.